Determination of pamidronate in bisphosphonate-enriched bone cement by ion-pair hplc and capillary electrophoresis

• Autorzy: Matuszewski L. , Matuszewska A. , Mazurkiewicz T. , Polkowska I. , Jaszek M. , Graz M. , Gagala J.
• Języki publikacji: EN

Abstrakty

EN

The presence of pamidronate during local use of bisphosphonates (BP)-enriched bone cement was determined. The question was whether pamidronate implanted into the bone cement is eluted. The study was performed on 10 probes of BP-enriched bone cement located in 0.9% NaCl. The probes were incubated for 3 and 6 weeks. Ion-pair HPLC was used for the detection of pamidronate. Then, capillary electrophoresis was applied for quantitative analysis of pamidronate in the 3rd and 6th week after incubation. The presence of pamidronate, eluted from BP-enriched bone cement into 0.9% NaCl solution 3 and 6 weeks after incubation, was demonstrated. These results may explain the changes in the level of cytokine RANKL and bone turnover marker osteoprotegrin in rats' serum treated with BP-enriched bone cement 3 and 6 weeks after surgery. The possibility of effective local use of BP-enriched bone cement in veterinary medicine was underlined. The results, and the former conducted research, point out that the clinical applications of BP-enriched bone cement in vivo may have some validity in the future.

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2013
• Tom: 57
• Numer: 2
• Opis fizyczny: p.257-262,fig.,ref.

Twórcy

autor

Matuszewski L.

• Paediatric Orthopedic and Rehabilitation Clinic, Medical University of Lublin, 20-093 Lublin, Poland

autor

Matuszewska A.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Mazurkiewicz T.

• Orthopaedic and Traumatology Department, Medical University of Lublin, 20-954 Lublin, Poland

autor

Polkowska I.

• Department and Clinic of Animal Surgery, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, 20-612 Lublin, Poland

autor

Jaszek M.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Graz M.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Gagala J.

• Orthopaedic and Traumatology Department, Medical University of Lublin, 20-954 Lublin, Poland

Bibliografia

• 1. Abu-Amer Y., Darwech I.: Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007, 9 (Suppl 1), S6.
• 2. Astrand J., Aspenberg P.: Reduction of instability- induced bone resorption using bisphosphonates. High doses are needed in rats. Acta Orthop Scand 2002, 73, 24- 30.
• 3. Bexheti D., Anderson E.I., Hutt A.J., Brown M.A.: Evaluation of multidimensional capillary electrophoretic methodologies for determination of amino bisphosphonate pharmaceuticals. J Chromatograph A 2006, 1130, 137-14.
• 4. Bock O., Börst H., Beller G., Armbrecht G., Degner C., Martus P., Roth H.J., Felsenberg D.: Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo nCT. Bone 2012, 50, 317-24.
• 5. Daley-Yates P., Gifford L., Hoggarth C.: Assay of 1-hydroxy-3-aminopropylidene-1,1-bisphosphonate and related bisphosphonates in human urine and plasma by high-performance ion chromatography. J Chromatogr B: Biomed Sci Appl 1989, 490, 329-338.
• 6. Fleisch H.: Bisphosphonates: mechanisms of action. Endcrinol Rev 1998, 19, 80-102.
• 7. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(ß, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12, 1358-1367.
• 8. Gao Y., Zou S., Liu X., Bao Ch., Jing H.: The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials 2009, 30, 1790-1796.
• 9. Geoffroy V., Paschalis E.P., Libouban H., Blouin S., Ostertag A., Chappard D., Cros M., Phipps R., de Vernejoul M.C.: Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. Calcif Tissue Int 2011, 88, 464-475.
• 10. Goldring S.R., Gravallese E.M.: Bisphosphonates: environmental protection for the joint? Arthritis Rheum 2004, 50, 2044-2047.
• 11. Goodship A.E., Blunn G.W., Green J., Coathup M.J.: Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008, 26, 693-703.
• 12. Huikko K., Kostiainen R.: Development and validation of a capillary zone electrophoresis method for the determination of bisphosphonate and phosphonate impurities in clodronate. J Chromatogr A 2000, 893, 411- 420.
• 13. Jakobsen T., Bass J., Bechtold J.E., Elmengaard B., Soballe K.: Soaking morselized allograft bone in bisphosphonate can impair implant fixation. Clin Orthop 2007, 463, 195-201.
• 14. Jia H.J., Li W., Zhao K.: Determination of risedronate in rat plasma samples by ion-pair high-performance liquid chromatography with UV detector. Anal Chim Acta 2006, 562, 171-175.
• 15. Kwong E., Chiu A.M.Y., McClintock S.A., Cotton M.L.: HPLC analysis of an amino bisphosphonate in pharmaceutical formulations using post-column derivatization and fluorescence detection. J Chromatogr Sci 1990, 28, 563-566.
• 16. Lewis G., Janna S.: Aldendronate in bone cement. Clin Orthop Rel Res 2006, 445, 233-238.
• 17. Makkonen N., Hirvonen M-R., Teräväinen T., Savolainen K., Mönkönen J.: Different effects of three bisphosphonates on nitric oxide production by Raw 264 macrophage-like cells in vitro. J Pharm Exp Ther 1996, 277, 1097-1102.
• 18. Marx R.E.: Pamidronate (Aredia) and zoledronate (Zometa) induced a vascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 2003, 61, 1115-1117.
• 19. Matuszewski Ł., Matuszewska A., Mazurkiewicz T., Rogalski J., Cho N.S., Ohga S.: Determination of bisphosphonates by ion-pair HPLC. J Fac Agr Kyushu Univ 2011, 56, 213-216.
• 20. Matuszewski Ł., Turżańska K., Matuszewska A., Jabłoński M., Polkowska I., Mazurkiewicz T.: Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro- computed tomography. International Orthopaedics. http://www.springer.com/alert/urltracking. do?id=Lfb8 d2bMbe6f65Saad8ca 1. Accessed 24 February 2013.
• 21. Mazurkiewicz T., Matuszewski Ł., Matuszewska A., Jaszek M.: Implanted bisphosphonates in bone cement affect bone markers in rat serum. International Orthopaedics. http://link.springer.com/article/10.1007/ s00264-013-1816-6. Accessed 26 January 2013.
• 22. Migliorati C.A.: Bisphosphonates and oral cavity bone necrosis. J Clin Oncol 2003, 21, 4253-4254.
• 23. Morris C.D., Einhorn T.A.: Bisphosphonates in orthopedic surgery. J. Bone Joint Surg 2005, 87, 1609- 1618.
• 24. Perjesi P., Kim T., Zharikova A.D., Li X., Ramesh T., Ramasubbu J., Prokai L.: Determination of clodronate content in liposomal formulation by capillary zone electrophoresis. J Pharma Biomed Anal 2003, 31, 929- 935.
• 25. Peter B., Gauthier O., Laib S., Bujoli B., Guicheux J., Janvier P.: Local delivery of bisphosphonate from coated orthopedic implants increases implant mechanical stability in osteoporotic rats. J Biomed Mater Res A 2006, 76, 133-143.
• 26. Prieto-Alhambra D., Javaid M., Judge A., Murray D., Carr A., Cooper C., Arden N.: Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 2011. http://dx.doi.org/10.1136/bmj.d722.
• 27. Rodriquez J.A.B., Desimone M.F., Iglesias S.L., Giorgieri S.A., Diaz L.E.: Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities. J Pharm Biomed Anal 2007, 44, 305-308.
• 28. Russell R.G.G., Rogers M.J.: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25, 97-106.
• 29. Schindeler A., Birke O., Yu N.Y., Morse A., Ruys A., Baldock P.A., Little D.G.: Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br 2011, 93, 1134- 1139.
• 30. Sirén H., Määttänen A., Riekkola M.L.: Determination of small anions by capillary electrophoresis using indirect UV detection with sulphonated nitrosonaphtol dyes. J Chromatogr A 1997, 767, 293-301.
• 31. Sparidans R.W., Hartigh J.: Chromatographic analysis of bisphosphonates. Pharm World Sci 1999, 21, 1-10.
• 32. Tomlin J.L., Sturgeon C., Pead M.J., Muir P.: Use of bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000, 147, 129-132.
• 33. Wilkinson J.M., Little D.G.: Bisphosphonates in orthopedic applications. Bone 2011, 49, 95-102.
• 34. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Grundker C., Hofbauer L.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291, 680-668.
• 35. Xie Z.X., Jiang Y., Zhang D.Q.: Simple analysis of four bisphosphonates simultaneously by reverse phase liquid chromatography using n-amylamine as volatile ion- pairing agent. J Chromatogr 2006, 1104, 173-178.
• 36. Xuenong Z., Qingyun X., Haishengen L., Bunger M., Lind M., Bunger C.: Effect of alendronate on bone in growth into porous tantalum and carbon fiber interbody devices. Acta Orthop Scand 2003, 74, 596-603.
• 37. Zacharis C.K., Tzanavaras P.D.: Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: A review of analytical methods. J Pharma Biomed Anal 2008, 48, 483-496.